Loading clinical trials...
Loading clinical trials...
A Single Arm Phase II Study to Investigate the Efficacy, Safety and Pharmacokinetics of a Single Dose of 200 mg of i.v. BI 2536, Administered Once Every 3 Weeks in Patients With Advanced Metastatic Hormone-refractory Prostate Cancer.
Conditions
Interventions
BI 2536
Locations
6
United Kingdom
1216.19.4407 Boehringer Ingelheim Investigational Site
Cambridge, United Kingdom
1216.19.4405 Boehringer Ingelheim Investigational Site
Guildford, United Kingdom
1216.19.4402 Boehringer Ingelheim Investigational Site
Headington, United Kingdom
1216.19.4406 The Christie NHS Foundation Trust
Manchester, United Kingdom
1216.19.4404 Boehringer Ingelheim Investigational Site
Newcastle upon Tyne, United Kingdom
1216.19.4401 Boehringer Ingelheim Investigational Site
Sutton, United Kingdom
Start Date
September 1, 2006
Primary Completion Date
February 1, 2008
Last Updated
May 16, 2014
NCT07225946
NCT04868604
NCT00756665
NCT05743621
NCT04104776
NCT06242119
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions